

SUPPLEMENTARY TABLES

Supplementary Table 1. The primers used in this study.

Gene name	Forward primers(5'-3')	Reverse primers(5'-3')
Inc-BMP1-1	TTCTGGAGATGAGCATTGGGG	AGTGGAGCCGATGGAGAAGGT
DNMT1	TTGGAGAACGGTGCTCATGCTTA	CATCTGCCATTCCCACTCTACGG
DNMT3a	GGCAAACCTGAGGTAGCGACA	AAAAAAAGGGAAGGGGGAG
DNMT3b	AAGAGTTGGGCATAAAGGTAGG	GCTGGATTACATTTGAGAGAT
Cav-1	GCAGCCTCCCTGAAGACCAAA	TGCCAGATGAAGCCCAGAAGT
ABCA3	TCTTCGAGCACCCCTTCAAC	GTAGTGTGCCAGCCTTCTGT
NPR1	TTGCTCGGCATTCTGATTGTCTC	CCTCTCAAGGCTACTGGGCTCAAC
β -actin	GGCGGCACCACCATGTACCCT	AGGGGCCGGACTCGTCATACT
GAPDH	GGAGTCAACGGATTTGGTCGTATTG	TCTCGCTCCTGGAAGATGGTGAT

Supplementary Table 2. Demographics and clinical characteristics of studied samples.

Clinical Characteristics	Southern Samples	Eastern Samples	Pearson χ^2	P value
	N (%)	N (%)		
Total	199(67.9)	94(32.1)		
Age(years)			0.325	0.569
	< 60	115(57.8)		
	≥ 60	84(42.2)		
Sex			0.013	0.910
	Female	58(29.1)		
	Male	141(70.9)		
Family history of cancer			0.666	0.414
	No	176(88.4)		
	Yes	23(11.6)		
Smoking			0.512	0.400
	No	72(36.2)		
	Yes	127(63.8)		
Drinking			0.183	0.270
	No	150(75.4)		
	Yes	49(24.6)		
Clinical Stage			2.794	0.192
	I+II	77(38.7)		
	III+IV	122(61.3)		
Histological types			1.842	0.771
	Adenocarcinoma	95(47.7)		
	Squamous cell carcinoma	56(28.1)		
	Large cell carcinoma	6(3.0)		
	Small cell lung cancer	21(10.6)		
	Other carcinomas*	21(10.6)		

*Mixed-cell or undifferentiated carcinoma